Aurinia Pharmaceuticals Inc. - Laporan Laba Rugi (TTM)

Aurinia Pharmaceuticals Inc.
DE ˙ DB ˙ CA05156V1022
€ 10.66 ↓ -0.05 (-0.51%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Aurinia Pharmaceuticals Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 0 50 51 58 72 46 66 88 129 134 147 160 159 176 191 207 220 235 247 260
Change (%) 42,735.90 1.76 12.92 25.42 -36.86 45.41 32.53 46.78 3.90 9.54 9.06 -0.79 10.49 9.06 8.20 6.40 6.70 5.17 5.18
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 50 50 46 46 54 6 55 58 19 51 10 52 59 64 64 62 51 49 50 52
Change (%) -0.24 -7.86 -1.46 17.68 -89.71 898.10 4.93 -66.41 160.25 -80.97 444.14 13.26 7.39 -0.43 -1.93 -18.13 -3.85 2.07 3.11
% of Revenue 43,116.24 100.42 90.92 79.34 74.45 12.13 83.28 65.94 15.09 37.79 6.56 32.75 37.39 36.34 33.18 30.08 23.14 20.85 20.24 19.84
Gross Operating Profit -50 -0 5 12 18 40 11 30 110 83 137 108 99 112 128 145 169 186 197 209
Change (%) -99.58 -2,314.83 157.01 55.15 117.10 -72.32 169.92 265.89 -23.88 64.52 -21.51 -7.63 12.34 14.47 13.23 16.95 9.88 5.99 5.71
% of Revenue -43,016.24 -0.42 9.08 20.66 25.55 87.87 16.72 34.06 84.91 62.21 93.44 67.25 62.61 63.66 66.82 69.92 76.86 79.15 79.76 80.16
SG&A 64 97 125 154 168 174 179 186 194 196 201 197 192 195 193 190 185 172 145 126
Change (%) 50.81 28.23 23.15 9.08 3.57 3.11 4.03 4.04 1.40 2.51 -2.21 -2.24 1.35 -1.25 -1.11 -2.83 -7.05 -15.90 -13.08
% of Revenue 55,126.50 194.09 244.57 266.71 231.97 380.52 269.81 211.79 150.13 146.51 137.11 122.94 121.14 111.12 100.63 91.96 83.98 73.16 58.50 48.35
R&D 47 32 42
Change (%)
% of Revenue 102.39 24.49 28.41
OpEx 131 154 179 206 228 226 234 245 245 246 250 243 249 261 254 254 239 223 205 197
Change (%) 17.69 15.78 15.03 11.03 -0.86 3.56 4.45 0.11 0.17 1.83 -2.61 2.26 4.95 -2.72 -0.01 -5.81 -7.01 -7.99 -3.82
% of Revenue 112,134.19 308.09 350.53 357.05 316.09 496.31 353.44 278.56 189.98 183.17 170.27 152.06 156.73 148.88 132.80 122.72 108.64 94.68 82.83 75.74
Operating Income -131 -104 -128 -148 -156 -181 -168 -157 -116 -111 -103 -83 -90 -86 -63 -47 -19 13 42 63
Change (%) -20.44 22.52 15.86 5.43 15.79 -7.01 -6.63 -26.03 -3.97 -7.44 -19.21 8.11 -4.80 -26.83 -25.06 -59.54 -165.76 239.24 48.60
% of Revenue -112,034.19 -208.09 -250.53 -257.05 -216.09 -396.31 -253.44 -178.56 -89.98 -83.17 -70.27 -52.06 -56.73 -48.88 -32.80 -22.72 -8.64 5.32 17.17 24.26
Interest Expense -0 -1 -3 -4 -5 -5 -5 -5 -5
Change (%) 2,153.85 89.42 46.23 27.92 -3.70 -3.28 -4.47 -1.75
% of Revenue -0.04 -0.92 -1.58 -2.12 -2.51 -2.27 -2.06 -1.87 -1.74
Net Income -129 -103 -127 -148 -156 -181 -168 -157 -115 -108 -97 -73 -77 -78 -63 -50 -23 6 40 61
Change (%) -20.44 23.81 16.10 5.51 16.21 -7.04 -6.83 -26.33 -6.30 -10.56 -24.83 6.13 1.07 -19.81 -19.52 -55.21 -125.51 592.72 52.18
% of Revenue -110,313.68 -204.88 -249.26 -256.27 -215.58 -396.81 -253.66 -178.32 -89.50 -80.71 -65.90 -45.42 -48.59 -44.45 -32.69 -24.31 -10.23 2.45 16.11 23.31

Source: Capital IQ

Other Listings
US:AUPH US$ 12.40
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista